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A Rare Case of Sotalol-Induced Respiratory Failure
Anh Do D.O, Zachary Demertzis D.O
Department of Internal Medicine
Henry Ford Health System, Detroit, Michigan
Background

Labs

• Beta-blockers (BB) is a class II antiarrhythmic
• Usually associated with respiratory adverse event such as exacerbations of
obstructive lung disease, hypersensitivity pneumonitis etc.
• Sotalol, a BB that has both class II and III antiarrhythmic activities, is
commonly used in the treatment and maintenance of atrial fibrillation or
atrial flutter.
• It is generally thought to associate with significantly lower pulmonary side
effects.
• The lower respiratory side effect profile does not eliminate its potential
risk, especially in patients who have a history of reactive airway disease.
• In this case, we will depict a rare case sotalol induced acute respiratory
failure

Case Description
• 71-year-old Caucasian female
• Past medical history:
– Atrial fibrillation due to severe mitral regurgitation
– Chronic obstructive pulmonary disease
– Coronary artery disease
– Breast cancer status post resection and radiation and amiodarone-induced
hypothyroidism
• Home medications: Albuterol MDI, Apixaban, Atorvastatin, Symbicort,
Lopressor, Spriva, Magnesium oxide, Senokot-S
• Chief complaint:
– Shortness of breath, productive cough, and palpitations for 2-day duration
that progressively worsened.
• Physical exam significant for
– Atrial flutter with RVR, other vital signs are stable
– No fever, chills, sore throat, wheezes, abdominal pain, nausea, vomiting,
diarrhea or constipation
• Hospital course:
– Cardizem infusion and continued her home Apixaban.
– Electrophysiology (EP) was consulted and she was started on Sotalol 80mg.
– A few hours after receiving the first dose of Sotalol, she was found to have
agonal respirations with diminished breath sounds, quickly requiring
intubation for respiratory distress.
– Sotalol was promptly discontinued. Approximately 12hrs after intubation,
she was successfully extubated to BiPAP and eventually weaned to 2-3L of
supplemental oxygen without any intervention such as diuresis, cardioversion
or COPD treatment.
– The patient remained in atrial flutter and thus discussions with EP and
Pulmonology decision was made to start on amiodarone but was unsuccessful
in achieving rate control.
– Underwent 200J direct-current cardioversion with success.
– Remained in sinus rhythm throughout the rest of her hospitalization and was
discharged shortly after

Imaging

Discussion
• The case illustrated that the potential risk of acute respiratory failure
with use of sotalol is a real concern.
• Pharmacokinetic profile of Sotalol
– Rapid onset of action (1-2 hours)
– Relatively short half-life (12 hours in adult).
• Most common side effects (> 10%)
– Cardiovascular: Bradycardia (dose related; 8% to 16%), chest pain
(3% to 16%), palpitations (3% to 14%)
– Central nervous system: Fatigue (dose related; 5% to 20%),
dizziness (3% to 20%), headache (2% to 12%)
– Neuromuscular & skeletal: Weakness (4% to 13%)
– Respiratory: Shortness of breath (dose related; 5% to 21%)
• Less common respiratory adverse event: Upper respiratory complaint
(1% to 8%), pulmonary disease (3% to 5%), tracheobronchitis (1% to
3%), asthma (<1% to 2%)
• Bronchial asthma or related bronchospastic conditions have been
listed as contraindication for the use of Sotalol
• No difference in adverse reaction profile between oral and IV Sotalol

Conclusion

Figure 1: Chest Xray before and after intubation

• Acute respiratory failure is infrequently seen but it is a predictable side effect
of sotalol use that physicians should be aware of, especially in patients with a
history of reactive airway disease
• Early recognition is crucial to the prompt cessation of Sotalol and prevention
of future adverse event. In the meantime, supportive treatment including
intubation could be enough to help the patient until the medication went
through its duration of action.
• Physician should consider patient’s past medical history when prescribing
medications like Sotalol
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Figure 2: Patient’s ECG indicating atrial flutter before initiating Sotalol

